WaveMan
WaveMan · Company
VKTX · Viking Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VKTX Viking Therapeutics (VKTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001607678
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
220
13F, latest reported quarter

What the filings say about VKTX

Insiders, 180 days
-$6.3M net sold
3 sellers · 0% of sales under a 10b5-1 plan

Viking Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Viking Therapeutics, Inc. insiders sold a net $6.3M of stock across 109 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lian Brian
President & CEO
SELL
2026-07-29 SEC
148,517
$4.9M
-24.8%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Jan 5, 2026.
  • The trade is 5.8% of the 2,572,441 shares held after it.
  • 2 other insiders sold within 30 days.
  • 220 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Lian Brian sold about $4.9M of VKTX on Jul 29, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 220 funds added in the latest 13F quarter.
Mancini Marianna
Chief Operating Officer
SELL
2026-07-29 SEC
18,217
$609.6K
-24.8%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Jan 5, 2026.
  • The trade is 4.3% of the 422,760 shares held after it.
  • 2 other insiders sold within 30 days.
  • 220 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Mancini Marianna sold about $609.6K of VKTX on Jul 29, 2026; 2 other insiders sold within 30 days and 220 funds added in the latest 13F quarter.
ZANTE GREG
Chief Financial Officer
SELL
2026-07-29 SEC
21,217
$710.1K
-24.8%
Context
  • 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Jan 5, 2026.
  • The trade is 10.0% of the 212,204 shares held after it.
  • 2 other insiders sold within 30 days.
  • 220 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer ZANTE GREG sold about $710.1K of VKTX on Jul 29, 2026; 2 other insiders sold within 30 days and 220 funds added in the latest 13F quarter.
Aubuchon Neil William
Chief Commercial Officer
BUY
2026-03-10 SEC
4,475
$149.9K
-30.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 4,475 shares held after it.
  • No other insider bought within 30 days.
  • 220 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Aubuchon Neil William bought about $149.9K of VKTX on Mar 10, 2026, the largest insider purchase at the company on our record; 220 funds added in the latest 13F quarter.
ZANTE GREG
Chief Financial Officer
SELL
2026-01-05 SEC
31,961
$1.0M
-22.9%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Oct 28, 2025.
  • The trade is 14.8% of the 215,571 shares held after it.
  • 3 other insiders sold within 30 days.
  • 220 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer ZANTE GREG sold about $1.0M of VKTX on Jan 5, 2026; 3 other insiders sold within 30 days and 220 funds added in the latest 13F quarter.
109 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 104 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$6.3M over 180 days
below 81% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
220 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
22.5% of the float short (float per yahoo 2026-10-27) · 4.4 days to cover · settled 2026-10-15
more than 96% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch VKTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-26.6%12M
-29%-11%+7%+24%2025-102025-122026-022026-042026-062026-082026-10 2026-07-29 · Lian Brian sold $4.9M2026-01-05 · Lian Brian sold $4.3M2025-10-27 · Rowland Charles A Jr sold $2.1M2026-01-05 · Lian Brian sold $1.8M2026-01-05 · Lian Brian sold $1.4M2025-10-28 · Lian Brian sold $1.4M2026-01-05 · ZANTE GREG sold $1.0M2026-01-05 · Mancini Marianna sold $1.0M2026-07-29 · ZANTE GREG sold $710.1K2026-07-29 · Mancini Marianna sold $609.6K2026-01-02 · FOEHR MATTHEW W sold $561.8K2026-01-05 · ZANTE GREG sold $464.0K2026-01-05 · Mancini Marianna sold $453.8K2026-01-05 · Mancini Marianna sold $359.3K2026-01-05 · ZANTE GREG sold $352.7K2026-01-05 · Lian Brian sold $224.4K2025-10-28 · Mancini Marianna sold $216.5K2025-10-28 · ZANTE GREG sold $216.5K2026-03-10 · Aubuchon Neil William bought $149.9K2026-01-05 · Mancini Marianna sold $56.1K2026-01-05 · ZANTE GREG sold $48.1K2026-07-29 · BRIAN LIAN filed to sell $4.9M2026-07-29 · MARIANNA MANCINI filed to sell $609.6K2026-07-29 · GREG ZANTE filed to sell $710.1K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VKTX: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
6,335,756 sh
$247.2M
BlackRock, Inc.
6,189,649 sh
$241.5M
STATE STREET CORP
5,606,394 sh
$218.7M
VANGUARD CAPITAL MANAGEMENT LLC
5,053,663 sh
$197.1M
VANGUARD PORTFOLIO MANAGEMENT LLC
4,484,263 sh
$174.9M

Congress trades in VKTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VKTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
BRIAN LIAN
Filed 2026-07-29
$4.9M
MARIANNA MANCINI
Filed 2026-07-29
$609.6K
GREG ZANTE
Filed 2026-07-29
$710.1K

VKTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Roundhill GLP-1 & Weight Loss ETF
$3.2M position · as of 2026-06-30
5.9%
Wasatch Ultra Growth Fund
$11.7M position · as of 2026-06-30
2.5%
ALPS Medical Breakthroughs ETF
$3.9M position · as of 2026-05-31
2.4%
Buffalo Mid Cap Discovery Fund
$6.1M position · as of 2026-06-30
1.8%
Nomura Healthcare Fund
$12.9M position · as of 2026-06-30
1.7%
Formidable ETF
$338.4K position · as of 2026-06-30
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
2 active
4
Phase 2
0 active
4
Phase 3
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$21.3M
$7.5M
$5.1M
+525%
+25%
2024
$14.3M
$106.8M
$4.7M
+615%
-7%
2023
$12.6M
$36.9M
$3.5M
+231%
-6%
2022
$5.4M
$13.3M
$1.9M
+67%
-10%
2021
$4.1M
$2.8M
$1.4M
-18%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $6.3M sold by insiders over 180 days, 220 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VKTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-88.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-79.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-92.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$0$0
Operating income-$393.3M-$150.9M-$100.8M-$70.4M
Net income-$359.6M-$110.0M-$85.9M-$68.9M
EPS (diluted)-3.19-1.01-0.91-0.90
Operating cash flow-$278.7M-$87.8M-$73.4M-$48.4M
Cash$165.8M$26.7M$55.5M$36.6M
Buybacksn/an/an/a$6.8M
SEC XBRL, fiscal years, as known on 2026-10-28

VKTX Stock Sonar score 4/7 axes

Find similar shapesCompare

VKTX ranks highest on institutional and government (92nd percentile) and profitability (32nd), and lowest on insider conviction (9th), among Pharma & Biotech peers.

Profitability
32
Inputs
  • Return on equity-88.9% · 37 pct, sector of 545
  • Return on assets-79.2% · 30 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-92.7% · 28 pct, sector of 576
Insider conviction
9
Inputs
  • Net Form 4 buying (codes P and S), 180d-$6.3M · 18 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
92
Inputs
  • Funds adding, latest quarter220 · 92 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
17
Inputs
  • Short interest, % of float+22.5% · 10 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+17.7% · 23 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

VKTX filings, in plain words

Are Viking Therapeutics insiders buying or selling VKTX?

In the 180 days to 2026-10-28, Viking Therapeutics insiders were net sellers, a net $6.3M across purchases and sales reported on Form 4, by 3 sellers.

Read the full summary

In the 180 days to 2026-10-28, Viking Therapeutics insiders were net sellers of VKTX, a net $6.3M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies